JLPC(SH:600513) Ge Long Hui·2025-12-26 09:01Core Viewpoint - The company has received a drug registration certificate for its product, Amlodipine Besylate Tablets, which is expected to enhance its product line and market competitiveness [1]. Group 1: Product Development - The company's subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., has been granted a drug registration certificate by the National Medical Products Administration for Amlodipine Besylate Tablets [1]. - The product is indicated for the treatment of primary hypertension in adults, with projected sales of approximately 58.73 million yuan in 2024 [1]. - The registration application for Amlodipine Besylate Tablets (40mg/80mg) was first submitted in August 2024 and has now been approved, signifying compliance with the consistency evaluation of generic drug quality and efficacy [1]. Group 2: Financial Investment - The research and development investment for Amlodipine Besylate Tablets has reached approximately 10.99 million yuan (unaudited) as of the announcement date [1]. - The company has obtained 10 production licenses for the product as of the announcement date [1]. Group 3: Market Impact - The acquisition of the drug registration certificate is expected to enrich the company's product line and enhance the competitiveness of its products in the market [1]. - The impact of this registration on the company's recent operating performance is not anticipated to be significant [1].